Josh Davis

Let me know if your fellows have any questions for the authors!

Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care:

doi.org/10.1186/s128...

#idsky #MedSky #HepSky #LiverSky

Making sense of hierarchical composite endpoints in randomized clinical trials – a primer for infectious disease clinicians and researchers Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,

Our review on hierarchical composite endpoints (HCEs) has just been published in @cidjournal.bsky.social:
doi.org/10.1093/cid/...

We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.

@steventong.bsky.social @gurujosh.bsky.social

Communicable E28: Late-breaker trials at ESCMID Global: Should they change your practice? - part 2 Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald...

🎙️ Just published a new #Communicable episode: Communicable E28: Late-breaker trials at ESCMID Global: Should they change ...

Hosted by Josh Davis @gurujosh.bsky.social
Erin McCreary @erinmccreary.bsky.social
Emily McDonald @dremilymcd.bsky.social

Listen here:

#IDSky #Clinmicro #MedSky

Communicable E27: Late-breaker trials at ESCMID Global: Should they change your practice? - part 1 This episode of Communicable takes on a special format where editors of...

🎙️ Just published a new #Communicable episode: Communicable E27: Late-breaker trials...

Hosted by Marc Bonten @marcbonten.bsky.social
Josh Davis @gurujosh.bsky.social
Erin McCreary @erinmccreary.bsky.social
Emily McDonald @dremilymcd.bsky.social

Listen here:

#IDSky #Clinmicro #MedSky

⏰ Tune in Monday for the latest #Communicable and hear the complete discussion w/ our editors on some of the late breaker trials at #ESCMIDGlobal '25, part 1! 🎙️

@gurujosh.bsky.social @dremilymcd.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @escmid.bsky.social

#IDSky #clinmicro

Has been great interacting with >850 orthopods and ID doctors from >50 countries at the www.icmortho.com meeting. Lots of interest in the #ROADMAPtrial!

SNAP Out of It: Rethinking Antistaphylococcal Penicillins for S. Aureus Bacteremia – The SNAP Trial PSSA/MSSA Results Podcast Episode · Breakpoints · 05/04/2025 · 1h 11m

such a joy to discuss PSSA/MSSA domains of SNAP. incredible work led by @gurujosh.bsky.social @steventong.bsky.social conversation w/ the fabulous @angelahuttner.bsky.social

joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast

podcasts.apple.com/us/podcast/s...

Debated for 40 years: Selective Decontamination of the Digestive tract in ICU patients (antibiotics to prevent ICU-acquired infections). My editorial to Josh Davis @gurujosh.bsky.social and Allen Cheng @peripatetical.bsky.social pro-con in @cmicomms.bsky.social.

www.cmi-comms.com/article/S295...

And thank you to @gurujosh.bsky.social & A Cheng for their pro-con piece on selective digestive decontamination (w/ #antibiotics) in #ICU patients

Whose side do you take?

#IDSky #Clinmicro #MedSky #PharmSky #AMR #ICUSky #Criticalcaresky @marcbonten.bsky.social

www.cmi-comms.com/article/S295...

SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultation...

The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?).
Huge congrats to Drs. Joshua Davis, Steven Tong, & the global team who made this ambitious trial happen. #IDSky blogs.jwatch.org/hiv-id-obser...

Yes. I think it’s mostly because X has mostly (but not completely) died for ID stuff and Bluesky is still not working as well as Twitter did at its peak

$5 million boost for world-first trial tackling strep infections in both children and adults A major new clinical trial, the Streptococcal Adaptive Platform (STRAP), has received $5 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) to improve treatment for life-threatening streptococcal infections across all age groups. Lead by researchers and clinicians from the Doherty Institute, Murdoch Children's Research Institute (MCRI), and other national and international partners.

SNAP is extending from S aureus to invasive streptococcal infections!

A new platform trial for iGAS and iSDSE

@gurujosh.bsky.social @joshosowicki.bsky.social @drmichaelmarks.bsky.social

www.doherty.edu.au/news-events/...

Taking a break from talking about #SNAPtrial to work on a new collaboration
#IDSky #ESCMIDglobal
@steventong.bsky.social

Yep me and most people I know will think twice (or thrice) before going to US conferences for the next few years

Alpha toxin at high concentration punches holes in host cells. At lower concentrations it binds to ADAM10 (present in many cell types) and thus indirectly causes cell death

Julianne Wardenberg on S.aureus pathogenesis at #ESCMIDglobal. Alpha toxin is a key virulence factor. First described by Frank Macfarlane Burnet in 1929!
#IDSky

We had not planned but can put this on the to do list!

I had not seen these data before. Is it published?

And in the big SNAP trial run 🏃‍♀️ for MSSA... it's cefazolin crossing the line ahead of (flu)cloxacillin 🏅

Cefazolin manufacturers are gonna have to really step up after this (still on shortage restrictions in 🇬🇧 😢)

RIP fluclox 🪦

@gurujosh.bsky.social gave an excellent talk 🥁

#ESCMIDGlobal

The most anticipated RCT in ID
🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia
N:1341
Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia
Cefazolin is non-inferior (90d mortality)& less AKI than ASPs
A practice-changer RCT that must change the guidelines
#ESCMIDGlobal #IDSky

#ESCMIDGlobal year in ID. Sumarry#1

#ESCMIDglobal year in ID Yoav Keynan #IDSky
Paper 6 - REGARD-VAP trial. Short course ABs (3-5 days) versus long course (>=8 days) for VAP in 39 Asian ICUs. No difference in mortality of recurrence, but shorter AB duration and less AEs in short course group.

#ESCMIDglobal year in ID Yoav Keynan #IDSky
Paper 5 - ADAPT sepsis trial
Daily PCT versus daily CRP versus no biomarkers to guide antibiotic cessation. PCT led to decrease in AB duration by 0.88 days. CRP was not useful.
Is 1 day shorter worth it?

#ESCMIDglobal year in ID Yoav Keynan
Paper 4- BALANCE (Daneman, NEJM 2024)
7 days non-inferior to 14 days of ABS for bacteraemia (not SAB).

#ESCMIDglobal year in ID
Paper 2 - BLING3 RCT (Dullhunty 2024 JAMA).
All cause mortality 24.9% CI versus 26.8% intermittent (7202 randomised). Clinical cure at day 14 better with CI
Combined with meta-analysis - probabiliy=99% that CI reduces mortality.

#ESCMIDglobal year in ID
DInh et al - RCT of all oral Rx for non-severe CAP. All oral non-inferior to IV. But small sample size, no quinolones used, many with CAP probably didn't have a bacterial infection #IDSky

Google Maps Find local businesses, view maps and get driving directions in Google Maps.

A reminder that SNAP results to be presented at #ESCMIDGlobal at:
'A trial run'
4.15-6.15 pm
Hall 13

PSSA - (flu)clox vs benzylpenicillin
MSSA - (flu)clox vs cefazolin

LOTs of time for questions!

Drinks right next to convention centre after: maps.app.goo.gl/Fc3WwH5aavrR...

Nice summary Paul. I feel like ICAAC was THE ID meeting for the world. Then it was ID Week and ECCMID. But now it’s clearly ESCMID Global (I think that was a strategic name change). Wish we had more North Americans here!

Looking Back at a Defunct ID Meeting -- and Ahead to a Thriving One Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising “bug-drug” studies of novel compound...

Remember ICAAC? Bad name, weirder pronunciation ("ick-kack"), ugly swag, and a classic case study in conference identity crisis.
A look back—and where the big ID trials land now, which is #ESCMID Global, or whatever it's called. #IDSky blogs.jwatch.org/hiv-id-obser...